

# ClÃ©ment Larrue

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/396196/publications.pdf>

Version: 2024-02-01

28  
papers

2,097  
citations

331670

21  
h-index

526287

27  
g-index

33  
all docs

33  
docs citations

33  
times ranked

3641  
citing authors

#	ARTICLE	IF	CITATIONS
1	APR-246 induces early cell death by ferroptosis in acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 403-416.	3.5	95
2	An <i>In Vivo</i> CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML. <i>Cancer Discovery</i> , 2022, 12, 432-449.	9.4	32
3	AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia. <i>Cell Reports</i> , 2022, 38, 110197.	6.4	22
4	Inhibition of the proteasome and proteophagy enhances apoptosis in FLT3-ITD-driven acute myeloid leukemia. <i>FEBS Open Bio</i> , 2021, 11, 48-60.	2.3	4
5	Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	56
6	Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells. <i>Nature Communications</i> , 2021, 12, 422.	12.8	36
7	Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. <i>Nature Cancer</i> , 2021, 2, 1204-1223.	13.2	42
8	AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 5966.	3.7	2
9	Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites. <i>Nature Communications</i> , 2020, 11, 4056.	12.8	96
10	Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo. <i>Cancers</i> , 2020, 12, 1725.	3.7	13
11	Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2020, 10, 1544-1565.	9.4	39
12	Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia. <i>Cancer Research</i> , 2019, 79, 5191-5203.	0.9	45
13	Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia. <i>Oncogenesis</i> , 2019, 8, 39.	4.9	26
14	Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2019, 102, 131-142.	2.2	57
15	Dexamethasone in hyperleukocytic acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, 988-998.	3.5	49
16	Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia. <i>Oncogene</i> , 2018, 37, 787-797.	5.9	82
17	RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 597-605.	7.2	22
18	Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. <i>Cancer Discovery</i> , 2017, 7, 716-735.	9.4	582

#	ARTICLE	IF	CITATIONS
19	Dendrogenin A drives LXR to trigger lethal autophagy in cancers. Nature Communications, 2017, 8, 1903.	12.8	84
20	Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. Blood, 2016, 127, 882-892.	1.4	108
21	CHK1 as a therapeutic target to bypass chemoresistance in AML. Science Signaling, 2016, 9, ra90.	3.6	73
22	Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. Journal of Experimental Medicine, 2016, 213, 483-497.	8.5	68
23	Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood, 2015, 126, 1346-1356.	1.4	303
24	Antileukemic Activity of 2-Deoxy-D-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations. Molecular Cancer Therapeutics, 2015, 14, 2364-2373.	4.1	52
25	A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia. Blood Cancer Journal, 2015, 5, e297-e297.	6.2	68
26	CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia. Oncotarget, 2015, 6, 38061-38078.	1.8	20
27	The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors. Leukemia, 2013, 27, 325-335.	7.2	17
28	IDH1 Mutation Enhances Catabolic Flexibility and Mitochondrial Dependencies to Favor Drug Resistance in Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , .	0.4	0